68 results on '"Villeval, Jean-Luc"'
Search Results
2. SRSF2-P95Hdelays Myelofibrosis Development through Altered JAK/STAT Signaling in JAK2-V617F Megakaryocytes
3. Palbociclib Prevents CDK4/6 Dependent-Myeloproliferation and Myelofibrosis
4. In VitroandIn VivoInteractions between Stromal and Leukemic Cells
5. Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage
6. Predicting the Long-Term Efficacy of Ifnα in JAK2V617F and Calr-Mutated MPN Patients
7. Differential Impact of Interferon Alpha on JAK2V617F and Calr Mutated Hematopoietic Stem and Progenitor Cells in Classical MPN
8. Specific and Synergistic Targeting of JAK2V617F Cells By Interferon Alpha and Arsenic
9. HSP27: A Therapeutic Target in Myelofibrosis
10. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis.
11. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
12. Complete Inhibition of STAT5 Phosphorylation Is Achieved By Combination of JAK1/2 and PI3K/mTOR Inhibitors in in Vitro and In Vivo MPN Models
13. Consequences of the Presence of the JAK2V617F Mutation in Endothelial Cells: Towards a Better Understanding of the Increased Angiogenesis in Myeloproliferative Neoplasms
14. Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis
15. Thrombopoietin Activates STAT2 Inducing Type I Interferon Effects and Gene Expression: Implications for in Vivo Tpo Treatment and for Myeloproliferative Neoplasms
16. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm
17. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
18. Effect Of The JAK1/2 Inhibitor GS-0387 (momelotinib) On The Anemia Associated With a Preclinical Murine Model Of Human Primary Myelofibrosis
19. The PI3K Specific Inhibitor BKM120 Results Effective and Synergizes With Ruxolitinib In Preclinical Models Of Myeloproliferative Neoplasms
20. Use Of 46/1 Haplotype Permits To Follow JAK2V617F Clonal Architecture In PV Patients: Clonal Evolution and Impact Of IFNα Treatment
21. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα
22. 46/1 Haplotype Permits to Follow JAK2 Homologous Recombination: Modeling JAK2V617F clonal Architecture in PV Patients
23. Combined Inhibition of JAK2 and mTOR Signaling Results in Enhanced Efficacy in in-Vitro and Preclinical Mouse Models of JAK2V617F-Driven Myeloproliferative Disease
24. Combination Treatment with JAK2 and PI3K Inhibitors in Myeloproliferative Neoplasms
25. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes
26. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene
27. The Cell Cycle Regulator CDC25A Is a Target for JAK2V617F Oncogene
28. Platelet Phenotype and Thrombosis In JAK2V617F Mice
29. JAK2V617F Promotes Stem Cell Amplification Driving MPN Clonal Dominance in Mice and Treatment by IFNa Prevents This Effect
30. Thrombospondin-1 is not the major activator of TGF-β1 in thrombopoietin-induced myelofibrosis
31. Notch/Delta4 signaling inhibits human megakaryocytic terminal differentiation
32. Novel Mutations: Dissecting Pathogenetic Contribution
33. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice
34. Interferon-Alpha Preferentially Targets JAK2V617F-Positive Rather Than Wild-Type Early Progenitor Cells in Myeloproliferative Disorders.
35. Constitutive Heterozygous Expression of JAK2V617F Mutated Kinase Triggers Severe Myeloproliferative Disorder in Knock-in Mice.
36. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines
37. Ligand-Independent MPLW515L Activity Requires Cell Surface Localization
38. Increased Myelofibrosis in Thrombospondin-1-Null Mice Is Associated with Enhanced TGF-β1-Mediated Response by Bone Marrow Fibroblasts
39. Activating mutations in human acute megakaryoblastic leukemia
40. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
41. JAK2 Activation Stimulates Homologous Recombination and Genetic Instability.
42. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice
43. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia
44. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis
45. Proteasome Inhibitor Bortezomib Can Inhibit Bone Marrow Fibrosis Development in a Murine Model of Myelofibrosis.
46. Gfi-1B plays a critical role in terminal differentiation of normal and transformed erythroid progenitor cells
47. Platelet activation induces metalloproteinase-dependent GP VI cleavage to down-regulate platelet reactivity to collagen
48. Human Platelet Glycoprotein VI: Identification of Residues Involved in the Binding to Collagen.
49. Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease
50. Cloning, characterization, and functional studies of human and mouse glycoprotein VI: a platelet-specific collagen receptor from the immunoglobulin superfamily
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.